esg401
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 14, 2021 (NCT04892342)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TACSTD2 inhibitor
Chemistry & pharmacology
- Payload
- SN38
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06732323 | Phase 3 | Feb 28, 2025 | Chinese Academy of Medical Sciences |
| NCT06383767 | Phase 3 | Jul 11, 2024 | Chinese Academy of Medical Sciences |
| NCT04892342 | Phase 1/Phase 2 (Phase 2) | Sep 14, 2021 | Chinese Academy of Medical Sciences, Government of China |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 2 | 2021 |
| Government of China | Government | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1